|
||
ARTICLE |
CORRESPONDENCE Matthew Collin: matthew.collin{at}ncl.ac.uk
|
|
|---|
© 2009 Haniffa et al.
Most interstitial tissues contain populations of resident DC and macrophages. In conventional descriptions, there is a division of labor between DC, which are dedicated to the induction and control of adaptive immunity (1, 2), and macrophages, which are occupied with the clearance of senescent cells, extracellular debris, and maintenance of tissue homeostasis (3, 4). According to mouse models, functional specialization is mirrored by differences in rates of turnover; DC transit rapidly through the tissues (5–7), whereas macrophages are predominantly "fixed" cells (8).
Recent studies of the human dermis have emphasized the apparent phenotypic differences between resident DC and macrophages (9, 10), whereas others have argued that conversion between macrophage and DC phenotypes might occur according to conditions of quiescence or inflammation (11–13). Many investigators have focused on migratory dermal DC that are more easily obtained in an enriched form and have value as a model of maturing DC (11, 14–20). Rather less progress has been made in characterizing human dermal DC and macrophages in a freshly isolated state (9, 10, 21, 22), and the relationship between migrant and resident APC populations remains unclear.
Hematopoietic stem cell transplantation is a powerful means of defining the ontogeny of BM-derived cells and has been previously used in humans to prove the BM origin of Langerhans cells (LC) (23), alveolar macrophages (24), and Kupffer cells (25). However, the lineage relationships of macrophages and DC are unknown because it has not been possible to analyze their turnover in the same organ with sufficient resolution. Understanding the ontogeny of BM-derived APC has many clinical implications. Tandem transplant experiments in mice have shown that competent recipient APC are required for the induction of acute graft versus host disease (GVHD) (26). It has generally been assumed, without rigorous proof, that DC are the predominant APC responsible for stimulating donor T cells (for review see references 27; 28). Specific recipient DC populations such as LC are indeed sufficient to induce GVHD (29), but other experimental systems show that macrophages may also play a role (30). According to current models, macrophage involvement in GVHD has principally been described in terms of their innate immune function, such as the production of TNF-
The search for persistent recipient APC in humans has been further promoted by a wealth of clinical data indicating that the risk of acute GVHD after immunosuppression withdrawal or donor lymphocyte infusion (DLI) remains significant for up to 12 mo after transplantation (33–38). It is known that recipient LC persist after donor hematopoietic stem cell engraftment, especially after reduced intensity conditioning, and that donor LC engraftment is stimulated by GVHD (39, 40). However, very few recipient LC persist after 3 mo (40, 41), indicating the potential involvement of other APC in promoting GVHD. Dermal APC are indirectly implicated in the pathogenesis of GVHD by many histopathological studies (42–46). We have also previously described recipient HLA-DR+ cells in dermis for at least 1 mo after transplantation in the absence of GVHD (47, 48).
In this study, we have investigated resident dermal DC and macrophages in human skin. We characterize their phenotypes and function in vitro, determine their kinetics of turnover during transplantation, and investigate their potential to stimulate allogeneic T cells through cytokine production and antigen-specific interactions. Our observations suggest that dermal macrophages outlive all other cutaneous APC and may have the capacity to promote GVHD through both innate inflammatory properties and antigen-specific stimulation of allogeneic T cell responses.
in response to IFN-
and LPS (31, 32), rather than through antigen-specific T cell stimulation.
![]()
RESULTS
Top
ABSTRACT
RESULTS
DISCUSSION
MATERIALS AND METHODS
REFERENCES
Human dermal APC defined
Upon 6–12-h collagenase digestion of freshly keratomed dermis, several populations of DAPI-negative cells are evident from analysis of autofluorescence (AF) and side scatter (SSC) alone (Fig. 1 A). These may be refined by successively gating on CD45+ cells, which includes DC, macrophages, mast cells, and lymphocytes, and then on HLA-DR+ cells, which excludes mast cells and lymphocytes, to produce two major fractions separable by SSC and AF: SSCloAFlo and SSChiAFhi. The SSChiAFhi fraction is especially fluorescent in channels excited by the 488-nm laser. In the experiments shown, AF was recorded in FL1.
|
There are consistent morphological differences between SSCloAFlo CD1a+CD14– and CD14+CD1a– subpopulations (Fig. 1 B). As shown in Figs. 1 and 2, CD14+ DC display several intermediate phenotypic and functional properties of CD1a+ DC and macrophages. We found no evidence to indicate that circulating monocytes contribute significantly to the CD14+ DC population. In particular, B cells, which are present at an
1:1 ratio with monocytes in blood, are equivalent to only 2–5% of the number of CD14+ cells present (unpublished data). In addition, monocytes have much higher CD52 and do not up-regulate HLA-DR to the same level after overnight exposure to medium from a dermal digest preparation (unpublished data).
|
In summary, the dermal macrophage may be defined as CD45+HLA-DR+SSChiAFhiCD14+CD1a–FXIIIa+. Two subsets of dermal DC are found in the CD45+HLA-DR+SSCloAFlo fraction that may be further divided by CD1a and CD14 expression. In the studies that follow, we use CD45, HLA-DR, SSC, AF, and CD14/CD1a for flow cytometry and HLA-DR, CD14, and FXIIIa for microscopy. As shown by others, CD163 may also substitute for FXIIIa in in situ studies of macrophages and, similar to FXIIIa, this is also detectable at low levels on CD14+ DC by flow cytometry (9, 20).
Functional properties of human dermal APC
Having defined three principal populations of dermal APC by surface phenotype, we compared the in vitro properties that conventionally separate DC from macrophages. After 72 h in culture, CD1a+ and CD14+ dermal DC migrate easily from dermal sheets, but the macrophages remain fixed (Fig. 2 A) and can only be recovered from the digested dermal "remnant." Freshly isolated CD1a+ DC have uniform CCR7 expression but macrophages remain negative and CD14+ DC are variable (Fig. 2 A). We attempted to induce migration of macrophages using a variety of inflammatory mediators, including GM-CSF, LPS, TNF-
, and IFN-
, but none of these stimuli induced them to leave the dermis or up-regulate expression of CCR7 (unpublished data). Differences in phagocytosis of FITC dextran (Fig. 2 B) and adherence to tissue culture plastic (Fig. 2 C) are also evident. These results are consistent with the classical view that DC are nonadherent cells with lower phagocytic activity than highly adherent macrophages. When freshly isolated, CD14+ DC show intermediate behavior.
Dermal macrophages, but not DC, survive conditioning
As a first step to defining the turnover of dermal APC during transplantation, we investigated their ability to survive conditioning therapy, the preparative regimen of cytoreductive drugs and total body irradiation which is given to patients before they receive allogeneic cells. Conditioning therapy depletes the blood of leukocytes but the effect on interstitial APC, such as dermal DC and macrophages, has not been previously studied.
We obtained pre- and postconditioning skin shave biopsies from patients scheduled for hematopoietic stem cell transplantation. Postconditioning biopsies were taken on day 0. Dermal DC and macrophages per unit area were measured by freshly digesting a standard area of dermis and counting the total number of cells by flow cytometry. We used a similar gating strategy to that defined in Fig. 1 to count CD1a+ DC, CD14+ DC, and macrophages (Fig. 3 A). This reveals rapid and selective depletion of CD1a+ DC but preservation of macrophages and CD14+ DC (Fig. 3 B). Selective depletion of CD1a+ DC is observed in patients receiving both reduced intensity conditioning, which does not completely ablate the hematopoietic stem cell compartment, and full intensity or myeloablative conditioning (Fig. 3 C; and see Table S1 [available at http://www.jem.org/cgi/content/full/jem.20081633/DC1] for further clinical details). CD14+ DC appear to increase slightly after full intensity conditioning, possibly reflecting some recruitment caused by cytotoxic injury. The preservation of dermal macrophages is also seen directly with immunofluorescence staining, using CD163 as an alternative marker to FXIIIa (Fig. 3 D). Because alemtuzumab (humanized anti-CD52 antibody) was a component of the conditioning regimen in this cohort of patients, we also determined the level of CD52 expression by different APC populations. As shown in Fig. 3 E, the expression of CD52 is much lower on dermal APC compared with dermal T cells, which are similar to peripheral blood T cells (not depicted). Although CD1a+ DC have slightly higher CD52 levels than CD14+ DC and macrophages, it appears unlikely that direct cytotoxicity by alemtuzumab is a major cause of differential depletion of DC in this cohort of patients.
|
A cohort of 52 patients was biopsied at intervals of 40, 100, and 365 d after transplantation (see Table S2 [available at http://www.jem.org/cgi/content/full/jem.20081633/DC1] for further clinical details). Biopsies were either digested freshly or split into migratory and digested remnant preparations. LC from epidermal sheets of the biopsies were also prepared for comparison. Fig. 4 A shows a migratory dermal preparation containing predominantly donor-derived CD14+ and CD14– DC. A single recipient FXIIIa+ macrophage is also present. A digested remnant preparation in Fig. 4 B contains mostly recipient macrophages and some residual donor-derived CD14– (CD1a+) DC. Regardless of the mode of sample preparation, we consistently observed higher donor engraftment of both subsets of DC than macrophages (Fig. S3 and Table S3 available at http://www.jem.org/cgi/content/full/jem.20081633/DC1). The pooled data are presented in Fig. 4 C. This shows that recipient CD14+ and CD14– DC are nearly completely replaced by 40 d, which is in synchrony with peripheral blood myeloid engraftment, but that a proportion of recipient macrophages remain for at least 365 d (Fig. 4 C). The prolonged survival of recipient dermal macrophages is striking. Their median engraftment is only 17% at 40 d and 46% at 100 d, with little evidence that GVHD promotes donor engraftment (Fig. 4 D). In most samples, there is a slightly greater retention of recipient HLA-DR+CD14+ DC than HLA-DR+CD14– DC, reaching statistical significance at day 100 (Fig. 4 C). We interpret this slight recipient bias as indicating a slightly slower turnover of CD14+ cells and as evidence against their potential role as precursors of the CD14– (CD1a+) DC. Comparison of the engraftment of dermal DC and LC proves that the majority of HLA-DR+CD14– dermal DC are not derived from migrating LC but have an independent turnover from the blood. Indeed, at 40 d, patients transplanted with reduced intensity conditioning in the absence of GVHD have a median of 43.1% donor LC but 87.7% donor dermal DC (Fig. 4 D). Occasional LC of recipient origin were observed among the migrating dermal cells but they were consistently <2% of HLA-DR+ cells.
|
|
To examine mechanisms that promote the survival of recipient macrophages, we measured DNA ploidy to determine their proliferative potential (Fig. 5 D). Both LC and CD1a+ dermal DC contain significant hyperdiploid fractions, 2.6 and 1.8% respectively, but CD14+ DC, macrophages, and lymphocytes are all <1%. Occasional binucleate, rather than G2/M-phase cells, probably account for 0.6% hyperdiploid macrophages because there is a virtual absence of any S-phase population and binucleate cells were occasionally observed on cytospin preparations (Fig. 5 D, inset). This observation is in keeping with their inability to migrate ex vivo and the notion that macrophages are fixed.
Dermal macrophages secrete inflammatory cytokines
The innate immune function of resident dermal macrophages has not been previously investigated, and the conventional role of macrophages in promoting GVHD by innate mechanisms is at odds with more recent descriptions of their regulatory role in tissues such as the gut (49, 50). Spontaneous and stimulated cytokine release was measured in comparison with blood monocytes (Fig. 6). Purified CD1a+ DC and macrophages were obtained by cell sorting freshly digested dermis. Cells were gated as outlined in Fig. 1 and purity after sorting was usually at least 95% and viability at least 90% (Fig. S4, available at http://www.jem.org/cgi/content/full/jem.20081633/DC1). Both DC and macrophages exhibit proinflammatory profiles with significant production of IL-1 and IL-6. This is particularly enhanced by peptidoglycan and poly-IC stimulation, including induction of TNF-
and IL-23. Dermal macrophages make little IL-10 and do not induce Foxp3+CD25hi regulatory cells from naive T cells in the presence of TGF-β (unpublished data). In these experiments, the blood monocyte was notable for a very sensitive response to LPS.
|
100-fold more potent than macrophages at stimulating naive CD4+ T cells (Fig. 7 A). Surprisingly, neither DC nor macrophages are able to stimulate much proliferation in memory CD4+ T cells, compared with anti-CD3/CD28 beads, although both cells induce significant IL-17 and IFN-
production compared with controls (Fig. 7 B). Macrophages are also able to stimulate proliferation, cytokine secretion, and expression of activation antigens by allogeneic CD8+ T cells. These responses are relatively efficient compared with dermal CD1a+ DC. Macrophages elicit
50% levels of proliferation and CD25 expression and similar levels of IFN-
production and CD69 expression compared with dermal DC (Fig. 7, C–E). These results confirm the classical view of macrophages as poor stimulators of naive T cells. They also highlight a recent and unexpected finding that tissue-derived myeloid DC may be much less efficient at stimulating memory T cell proliferation than previously assumed (51). Finally, the ability of macrophages to induce cytokine responses in memory CD4+ T cells and stimulate CD8+ T cells suggests that they could potentiate the responses of alloreactive T cells during transplantation.
|
| DISCUSSION |
|---|
|
|
|---|
We have presented a comprehensive analysis of dermal APC that allows us to understand not only previous data using dual immunofluorescence to study DC and macrophages in situ (9, 10) but also more functional studies that have focused on the isolation of different skin migratory DC populations (11, 14–20). We find three principal subsets of myeloid cells in human dermis: HLA-DR+CD14–CD1a+ DC; HLA-DR+CD14+CD1a– DC and HLA-DR+CD14+CD1a–FXIIIa+ dermal macrophages. The CD14+ DC migrates in vitro but retains some intermediate properties of both DC and macrophages. As a migratory cell, recent evidence indicates that it has a specialized function in priming follicular helper CD4+ T cells (20). Most previous reports have not fully accounted for the existence of three distinct populations. Studies on migratory cells containing CD1a+ and CD14+ DC are unable to determine the origin of these cells in situ because they do not account for the major population of macrophages, which share a number of markers with CD14+ DC but do not migrate. In situ studies have focused on two populations, CD1a+ DC and macrophages, but do not define the place of the CD14+ DC (9, 10). Others, using freshly digested dermis, have not explicitly excluded macrophages from the CD14+ DC subset. This potentially distorts the characterization of freshly isolated CD14+ DC and makes them appear more like macrophages when they are compared with CD1a+ DC (11, 16, 18).
Human dermal macrophages can be distinguished by SSC and AF and constitute up to 40% of CD45+HLA-DR+ dermal cells. Their characteristic physical properties are a result of the ingestion of huge quantities of melanin. Tattoo pigment ingestion by dermal macrophages was recently highlighted (9), but our data suggests that melanin uptake is a significant physiological function in normal skin. Indeed the term "melanophage," which is usually reserved for describing phagocytes seen in hyperpigmentation disorders or melanotic lesions (52–55), is entirely appropriate. Macrophages are marked by CD14, CD163, and FXIIIa as previously noted (9, 56, 57). We demonstrated the specificity of FXIIIa staining on cytospins by showing that it colocalizes with large cells containing melanosomes. A similar pattern of staining is observed in vitro. Flow cytometry reveals low level expression of FXIIIa by DC as previously reported (9, 14, 20), but the level is approximately tenfold lower than on macrophages.
Low SSC, nonautofluorescent CD45+HLA-DR+ cells of the dermis contain the two migratory APC of the dermis characterized by the expression of CD1a and CD14, respectively. Previous comparisons of skin migratory or in vitro–derived CD1a+ and CD14+ cells have concluded that the CD14+ is a form of immature or specialized DC (18, 19, 58, 59). The most recent of these analyses shows that migratory CD14+ DC have a specific function in priming follicular helper T cells (20). Others have suggested additionally that a component of these cells can differentiate into LC (16) or macrophages (11). Because the CD14+ DC has slightly delayed engraftment relative to the CD1a+ cell, it cannot be an immediate precursor of CD1a+ DC. Indeed, its phagocytic properties, lack of DNA synthesis, and morphology are reminiscent of dermal macrophages. It could be argued that the CD14+ cells, or at least a subset of them, are precursors of macrophages that have just not yet acquired a niche in the dermis. Further studies will be required to clarify that these cells actually traffic to the LN. Certainly, in vitro studies suggest a much inferior migratory capacity in response to CCR7 ligands (18). Although it is conceivable that circulating monocytes might be included among the dermal CD14+ population, we found little evidence to support this.
Having defined the myeloid cells of human dermis in detail, we examined their replacement during hematopoietic stem cell transplantation. After conditioning therapy, CD1a+ dermal DC are rapidly depleted, whereas CD14+ DC and macrophages are retained. After transplantation, both dermal DC are replaced by cells from the donor within weeks, but macrophages remain at least partly of recipient origin for >1 yr. This result supports the view that resident macrophages and immature DC are two distinct lineages at the tissue level, even though they share some markers and physiological attributes and are ultimately both BM derived. It is unlikely that resident macrophages are able to mature into migratory myeloid DC but more conceivable that they retain a distinct functional role in the dermis, even during inflammation. Their survival is consistent with our previous observation that a fraction of human HLA-DR+ dermal cells remain recipient in origin for at least 1 mo after transplantation (47). Prior reports of human alveolar macrophages and Kupffer cells have emphasized their BM origin and described complete donor engraftment within 3 mo (24, 25). Neither alveolar macrophages nor Kupffer cells may be typical of interstitial macrophages resident within epithelia such as the skin and gut. Unlike recipient LC, which turn over in response to inflammation, recipient macrophages survive GVHD and can be found in the perivascular regions of inflamed skin, interacting with T cells. They are progressively replaced by donor cells but with relatively invariant kinetics. There are also marked differences in the turnover of epidermal LC compared with dermal DC, which is most easily seen after reduced intensity conditioning. This reinforces the idea that LC have self-renewal capacity in humans.
The importance of the innate response of recipient macrophages to the induction of GVHD is well accepted (31, 32, 60). However, direct observations on human macrophages are scarce. Moreover, recent studies in the gut have assigned an antiinflammatory role to tissue macrophages through the production of IL-10 and fostering of regulatory T cell development (49, 50). Our results show, in contrast, that dermal macrophages are natural producers of IL-1 and IL-6 and synthesize TNF-
and IL-23 upon stimulation. Compared with monocytes, dermal macrophages are more polarized to respond to peptidoglycan and poly IC than to LPS, presumably reflecting the range of gram positive and viral pathogens they are likely to encounter in the skin.
We argue that in addition to providing critical inflammatory signals, recipient macrophages may also have the capacity to enhance GVHD through antigen-specific means by presenting host tissue antigens. This concept has precedence in mouse data showing that macrophages can play a primary role in the induction of antigen-specific cellular immunity (61) and allogeneic responses (62). Experiments using clodronate liposome-treated mice also suggest a role for local resident macrophages in recruiting and targeting T cells to sites of GVHD (30).
Testing the function of human APC in alloreactivity is complex because it is not immediately apparent in humans whether CD4+ or CD8+ T cells or both must be activated to induce GVHD or whether naive or memory T cell subsets contain the critical alloreactive populations. Lymphocyte recirculation must also be considered. Memory CD4+ T cells form the bulk of dermal T cells in normal skin (63, 64), and it is therefore unlikely that nonmigratory macrophages come into contact with naive CD4+ T cells, at least under quiescent conditions. However, a direct interaction with CD8+ T cells is possible because we have consistently observed CD8+ T cells in the dermis of transplant patients, even in the absence of clinical GVHD (unpublished data).
We were initially surprised to find that there was almost no proliferative response of memory CD4+ T cells to allogeneic DC or macrophages, given that memory cells are known to have a lower threshold for proliferation when stimulated via CD3/CD28 ligation (65). However, recent in vivo data show that migratory myeloid DC are very inefficient at stimulating the proliferation of CD8+ memory cells (51). The mechanism of this remains unknown and there are no previous studies in humans testing the proliferative response of memory CD4+ T cells to primary tissue DC. Recent work using in vitro–derived DC shows stimulation of memory CD4+ cell cytokine responses, which is consistent with our findings (20). An additional possibility that we cannot exclude is that the CD4+ memory T cell population in humans may not contain alloreactive cells, as has been described in mouse systems (66, 67).
Overall, it is unlikely that recipient macrophages are sufficient to induce acute GVHD, but their ability to stimulate cytokine production by memory CD4+ T cells and to activate CD8+ T cells is consistent with a role in which they may potentiate allogeneic responses locally. Clinically, this could contribute to relapses of acute GVHD mediated by antigen-experienced T cells after immunosuppression withdrawal in the manner of a secondary viral infection (68). Immunosuppression is frequently maintained until 3 mo after transplantation in humans, long after the replacement of DC and LC, but not macrophages, by donor cells. In addition, there are clear threshold effects to GVHD induction by DLI in humans (34–38), and persistent recipient macrophages could promote post-DLI GVHD by raising the frequency of alloreactive T cells above a critical level. Recipient macrophages in a number of sites might also contribute to chronic GVHD, and provide a source of recipient hematopoietic minor histocompatibility antigen, to stimulate graft versus leukemia responses.
In conclusion, this study provides a comprehensive description and functional analysis of human dermal APC, with sufficient resolution to demonstrate the differences in replacement of DC and macrophages after hematopoietic stem cell transplantation. We find evidence that dermal DC and macrophages are independent lineages and that surviving macrophages may have the potential to sustain graft versus host responses long after recipient DC have been eliminated.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Naive and memory CD4+ T cells were isolated to >90% purity by automated magnetic negative selection using EasySep human naive and memory CD4+ T cell isolation kits and RoboSep (StemCell Technologies Inc.) from peripheral blood mononuclear cells. CD8+ T cells were isolated to >95% purity by negative selection using RosetteSep CD8+ T cell isolation cocktail from whole blood (StemCell Technologies Inc.). Monocyte-derived DC were generated from magnetically isolated CD14+ monocytes (Miltenyi Biotec) and cultured for 6 d with 50 ng/ml GM-CSF and IL-4 (R&D Systems), followed by 24-h activation with 0.1 µg/ml LPS (Sigma-Aldrich), 10 ng/ml IL-1β (PeproTech), and 10 ng/ml TNF-
(PeproTech).
Flow cytometry.
Flow cytometry was performed with LSRII and FACSCalibur cytometers (BD) and data was analyzed with FlowJo (Tree Star, Inc.). Intracellular staining was performed after fixation and permeabilization with Cytofix/Cytoperm and Perm/Wash reagents (BD). 70,000 MW FITC coated-dextran particles were obtained from Sigma-Aldrich. For determination of DNA ploidy, cells were surfaced stained, washed, and fixed with 0.5% paraformaldehyde for 5 min. This was followed by a subsequent wash, further fixation with 50% cold ethanol for 30 min, and a final wash before resuspending in 2 µg/ml DAPI solution. The following antibodies were supplied by BD unless stated otherwise and are denoted as antigen fluorochrome (clone): CD1a FITC (NA1/34; Dako); CD1a APC (HI 149); CD1c APC (AD5-8E7; Miltenyi Biotec); CD3 PE (SK7); CD11b PE (ICRF 44); CD11c APC (B-ly6); CD14 PE and PECy7 (M5E2); CD45 APC Cy7 (2D1); CD80 PE (L307.4); CD83 APC (HB15); CD86 APC (2331:FUN-1); CD163 APC (215927; R&D Systems); HLA-DR FITC, APC, and PerCP Cy5.5 (L243); CCR7 APC (150503; R&D Systems); IL-17A Alexa Fluor 647 (eBio64DEC17; eBioscience); IFN-
FITC (25723.11); FXIIIa (sheep polyclonal; Enzyme Research Laboratories) with APC-conjugated donkey anti–sheep (Invitrogen); CD52 PE (YTH34.5; AbD Serotec).
Microscopy.
Laser confocal microscopy was performed using a confocal microscope (TCS SP2; Leica). Fluorescence microscopy was performed using a microscope (Axioplan 2; Carl Zeiss, Inc.). The following antibodies were used to stain paraffin-embedded sections: HLA-DR (L243; BD); FXIIIa (sheep polyclonal; Enzyme Research Laboratories); CD3 (rabbit polyclonal; Abcam); CD163 (NCL-CD163; Leica). The following secondary detection reagents were supplied by Invitrogen: Alexa Fluor 555–conjugated goat anti–rabbit, Alexa Fluor 568–conjugated goat anti–mouse, Alexa Fluor 633–conjugated donkey anti–sheep, and Alexa Fluor 633–conjugated goat anti–mouse.
Enumeration of dermal DC and macrophages.
Shave biopsies were cut with a 2-mm punch and digested with dispase to separate the epidermis and obtain a 3.14-mm2 disk of dermis. This was further digested with 0.8 mg/ml of collagenase for 12 h and dispersed to obtain a single cell suspension. Cells were washed once, stained with antibodies to CD45, HLA-DR, CD14, and CD1a, washed again, and transferred to 400 µl of buffer in a Trucount tube (BD). 30,000–50,000 events were recorded. Reproducibility of biopsy procedure and cell preparation was monitored by recording the weight and the fibroblast content.
Chimerism analysis.
Dermal cells prepared from clinical biopsies were harvested by spinning onto cytospin slides at 800 rpm for 5 min using a cytocentrifuge (Shandon Cytospin 4; Thermo Fisher Scientific). Cytospin slides were air dried and stored at –20°C before sequential immunofluorescence and FISH. Slides were thawed and fixed in methanol then stained with antibodies to CD14 (rabbit polyclonal; Abcam), CD3 (SK7; BD), and FXIIIa (AC-1A1; Abcam) combined with secondary Alexa Fluor 555–conjugated goat anti–rabbit and Alexa Fluor 633–conjugated goat anti–mouse IgG1 (Invitrogen) and directly conjugated anti–HLA-DR FITC. 10–12 x 40 four-color images were acquired by confocal microscopy and assembled into montages using Photoshop CS2 (Adobe). Cytospin slides were then fixed with methanol/acetic acid 3:1 for 5 min, probed with CEP X/Y DNA probes (Vysis; Abbott Molecular), mounted with Vectastain containing DAPI (Vector Laboratories), and scored for X/Y hybridization. Migratory LC were processed in a similar manner as previously described (40). Together, a total of 18,370 interphase nuclei were examined in 149 samples taken from 52 patients.
Dermal APC stimulation with TLR ligands.
4 x 104 flow-sorted dermal macrophages or DC were cultured in 96-well flat-bottomed plates. Supernatant from unstimulated and cells stimulated with 0.1 µg/ml LPS (Sigma-Aldrich), 10 ng/ml peptidoglycan (InvivoGen), and 10 µg/ml poly I:C (InvivoGen) were collected after 24 h of culture for cytokine analysis. TNF-
, IL-1, IL-6, IL-10, and IL-12p70 were detected using cytometric bead arrays (CBA-Flex; BD) and analyzed with Array software v1.0 (BD), and IL-23 was detected by ELISA (p19/p40; eBioscience).
Proliferation and T cell cytokine production assays.
104 flow-sorted dermal macrophages or DC were cultured with 105 allogeneic naive CD4+, memory CD4+, or CD8+ T cells in round-bottomed 96-well plates. CD3/28 beads were used at 1:1 ratio. On day 5 of alloreaction, the cultures received a 16-h pulse of 0.548 Mbq/ml [3H]thymidine (TRA310; GE Healthcare). Thymidine incorporation was measured using a luminescence counter (MicroBeta TriLux; PerkinElmer). CD25 and CD69 expression on CD8+ T cells were analyzed on day 5 of alloreactions. Supernatant from CD8+ alloreactions were collected on day 5 for IFN-
analysis using cytometric bead array (BD). On day 6 of alloreactions, memory CD4+ T cells were stimulated with 50 ng/ml PMA (Sigma-Aldrich) and 500 ng/ml ionomycin (Sigma-Aldrich) for 5 h in the presence of 10 µg/ml brefeldin A (Sigma-Aldrich) for the last 4 h before intracellular staining for IFN-
and IL-17.
Statistical analyses.
Mann-Whitney U and Wilcoxon Rank Sum tests were performed using Prism 4.0 (GraphPad Software, Inc.). All p-values are two tailed.
Online supplemental material.
Fig. S1 A shows the expression of FXIIIa in situ by immunofluorescence and correlates this with macrophages containing intracellular melanosomes. Fig. S1 B shows the relative messenger RNA expression of FXIIIa in CD1a+ DC, CD14+ DC, and macrophages. Fig. S2 gives additional examples of cytospin preparations used to determine posttransplant engraftment of APC and Fig. S3 shows that similar results are obtained using freshly digested, migrated, or remnant digest preparations. Fig. S4 shows purity after sorting of CD1a+ DC and macrophages used in the functional studies of the paper. Table S1 describes patients analyzed before and after conditioning therapy. Table S2 shows patients analyzed for dermal APC chimerism. Table S3 presents the raw data used for chimerism analysis. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20081633/DC1.
| Acknowledgments |
|---|
This work was funded by the Leukaemia Research Fund (UK), Action Medical Research, Histiocytosis Association of America, Tyneside Leukaemia Research Association, and Newcastle Healthcare Charity.
The authors have no conflicting financial interests.
Submitted: 25 July 2008
Accepted: 18 December 2008
| REFERENCES |
|---|
|
|
|---|
Steinman, R.M., D.S. Lustig, and Z.A. Cohn. 1974. Identification of a novel cell type in peripheral lymphoid organs of mice. III. Functional properties in vivo. J. Exp. Med. 139:1431–1445.[Abstract]
Ueno, H., E. Klechevsky, R. Morita, C. Aspord, T. Cao, T. Matsui, T. Di Pucchio, J. Connolly, J.W. Fay, V. Pascual, et al. 2007. Dendritic cell subsets in health and disease. Immunol. Rev. 219:118–142.[CrossRef][Medline]
Lee, S.H., P.M. Starkey, and S. Gordon. 1985. Quantitative analysis of total macrophage content in adult mouse tissues. Immunochemical studies with monoclonal antibody F4/80. J. Exp. Med. 161:475–489.
Gordon, S., and P.R. Taylor. 2005. Monocyte and macrophage heterogeneity. Nat. Rev. Immunol. 5:953–964.[CrossRef][Medline]
Steinman, R., L. Hoffman, and M. Pope. 1995. Maturation and migration of cutaneous dendritic cells. J. Invest. Dermatol. 105:2S–7S.[CrossRef][Medline]
Kissenpfennig, A., S. Henri, B. Dubois, C. Laplace-Builhe, P. Perrin, N. Romani, C.H. Tripp, P. Douillard, L. Leserman, D. Kaiserlian, et al. 2005. Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells. Immunity. 22:643–654.[CrossRef][Medline]
Ginhoux, F., M.P. Collin, M. Bogunovic, M. Abel, M. Leboeuf, J. Helft, J. Ochando, A. Kissenpfennig, B. Malissen, M. Grisotto, et al. 2007. Blood-derived dermal langerin+ dendritic cells survey the skin in the steady state. J. Exp. Med. 204:3133–3146.
Kennedy, D.W., and J.L. Abkowitz. 1997. Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model. Blood. 90:986–993.
Zaba, L.C., J. Fuentes-Duculan, R.M. Steinman, J.G. Krueger, and M.A. Lowes. 2007. Normal human dermis contains distinct populations of CD11c+BDCA-1+ dendritic cells and CD163+FXIIIA+ macrophages. J. Clin. Invest. 117:2517–2525.[CrossRef][Medline]
Ochoa, M.T., A. Loncaric, S.R. Krutzik, T.C. Becker, and R.L. Modlin. 2008. "Dermal dendritic cells" comprise two distinct populations: CD1+ dendritic cells and CD209+ macrophages. J. Invest. Dermatol. 128:2225–2231.[CrossRef][Medline]
de Gruijl, T.D., C.C. Sombroek, S.M. Lougheed, D. Oosterhoff, J. Buter, A.J. van den Eertwegh, R.J. Scheper, and H.M. Pinedo. 2006. A postmigrational switch among skin-derived dendritic cells to a macrophage-like phenotype is predetermined by the intracutaneous cytokine balance. J. Immunol. 176:7232–7242.
Nestle, F.O., and B.J. Nickoloff. 2007. Deepening our understanding of immune sentinels in the skin. J. Clin. Invest. 117:2382–2385.[CrossRef][Medline]
Hume, D.A. 2008. Macrophages as APC and the dendritic cell myth. J. Immunol. 181:5829–5835.
Nestle, F.O., X.G. Zheng, C.B. Thompson, L.A. Turka, and B.J. Nickoloff. 1993. Characterization of dermal dendritic cells obtained from normal human skin reveals phenotypic and functionally distinctive subsets. J. Immunol. 151:6535–6545.[Abstract]
Lenz, A., M. Heine, G. Schuler, and N. Romani. 1993. Human and murine dermis contain dendritic cells. Isolation by means of a novel method and phenotypical and functional characterization. J. Clin. Invest. 92:2587–2596.[Medline]
Larregina, A.T., A.E. Morelli, L.A. Spencer, A.J. Logar, S.C. Watkins, A.W. Thomson, and L.D.J. Falo. 2001. Dermal-resident CD14+ cells differentiate into Langerhans cells. Nat. Immunol. 2:1151–1158.[CrossRef][Medline]
Morelli, A.E., J.P. Rubin, G. Erdos, O.A. Tkacheva, A.R. Mathers, A.F. Zahorchak, A.W. Thomson, L.D.J. Falo, and A.T. Larregina. 2005. CD4+ T cell responses elicited by different subsets of human skin migratory dendritic cells. J. Immunol. 175:7905–7915.
Angel, C.E., E. George, A.E. Brooks, L.L. Ostrovsky, T.L. Brown, and P.R. Dunbar. 2006. Cutting edge: CD1a+ antigen-presenting cells in human dermis respond rapidly to CCR7 ligands. J. Immunol. 176:5730–5734.
Angel, C.E., A. Lala, C.J. Chen, S.G. Edgar, L.L. Ostrovsky, and P.R. Dunbar. 2007. CD14+ antigen-presenting cells in human dermis are less mature than their CD1a+ counterparts. Int. Immunol. 19:1271–1279.
Klechevsky, E., R. Morita, M. Liu, Y. Cao, S. Coquery, L. Thompson-Snipes, F. Briere, D. Chaussabel, G. Zurawski, A.K. Palucka, et al. 2008. Functional specializations of human epidermal langerhans cells and CD14+ dermal dendritic cells. Immunity. 29:497–510.[CrossRef][Medline]
Meunier, L., A. Gonzalez-Ramos, and K.D. Cooper. 1993. Heterogeneous populations of class II MHC+ cells in human dermal cell suspensions. Identification of a small subset responsible for potent dermal antigen-presenting cell activity with features analogous to Langerhans cells. J. Immunol. 151:4067–4080.[Abstract]
McLellan, A.D., A. Heiser, R.V. Sorg, D.B. Fearnley, and D.N. Hart. 1998. Dermal dendritic cells associated with T lymphocytes in normal human skin display an activated phenotype. J. Invest. Dermatol. 111:841–849.[CrossRef][Medline]
Volc-Platzer, B., G. Stingl, K. Wolff, W. Hinterberg, and W. Schnedl. 1984. Cytogenetic identification of allogeneic epidermal Langerhans cells in a bone-marrow-graft recipient. N. Engl. J. Med. 310:1123–1124.[Medline]
Thomas, E.D., R.E. Ramberg, G.E. Sale, R.S. Sparkes, and D.W. Golde. 1976. Direct evidence for a bone marrow origin of the alveolar macrophage in man. Science. 192:1016–1018.
Gale, R.P., R.S. Sparkes, and D.W. Golde. 1978. Bone marrow origin of hepatic macrophages (Kupffer cells) in humans. Science. 201:937–938.
Shlomchik, W.D., M.S. Couzens, C.B. Tang, J. McNiff, M.E. Robert, J. Liu, M.J. Shlomchik, and S.G. Emerson. 1999. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 285:412–415.
Shlomchik, W.D. 2003. Antigen presentation in graft-vs-host disease. Exp. Hematol. 31:1187–1197.[CrossRef][Medline]
Chakraverty, R., and M. Sykes. 2007. The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood. 110:9–17.
Merad, M., P. Hoffmann, E. Ranheim, S. Slaymaker, M.G. Manz, S.A. Lira, I. Charo, D.N. Cook, I.L. Weissman, S. Strober, and E.G. Engleman. 2004. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat. Med. 10:510–517.[CrossRef][Medline]
Zhang, Y., W.D. Shlomchik, G. Joe, J.P. Louboutin, J. Zhu, A. Rivera, D. Giannola, and S.G. Emerson. 2002. APCs in the liver and spleen recruit activated allogeneic CD8+ T cells to elicit hepatic graft-versus-host disease. J. Immunol. 169:7111–7118.
Nestel, F.P., K.S. Price, T.A. Seemayer, and W.S. Lapp. 1992. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor
during graft-versus-host disease. J. Exp. Med. 175:405–413.
Hill, G.R., J.M. Crawford, K.R. Cooke, Y.S. Brinson, L. Pan, and J.L. Ferrara. 1997. Total body irradiation and acute graft-versus-host disease: the role of gastrointestinal damage and inflammatory cytokines. Blood. 90:3204–3213.
Kolb, H.J., J. Mittermuller, C. Clemm, E. Holler, G. Ledderose, G. Brehm, M. Heim, and W. Wilmanns. 1990. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 76:2462–2465.
Mackinnon, S., E.B. Papadopoulos, M.H. Carabasi, L. Reich, N.H. Collins, F. Boulad, H. Castro-Malaspina, B.H. Childs, A.P. Gillio, N.A. Kernan, et al. 1995. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 86:1261–1268.
Marks, D.I., R. Lush, J. Cavenagh, D.W. Milligan, S. Schey, A. Parker, F.J. Clark, L. Hunt, J. Yin, S. Fuller, et al. 2002. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood. 100:3108–3114.
Guglielmi, C., W. Arcese, F. Dazzi, R. Brand, D. Bunjes, L.F. Verdonck, A. Schattenberg, H.J. Kolb, P. Ljungman, A. Devergie, et al. 2002. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood. 100:397–405.
Peggs, K.S., K. Thomson, D.P. Hart, J. Geary, E.C. Morris, K. Yong, A.H. Goldstone, D.C. Linch, and S. Mackinnon. 2004. Dose-escalated donor lymphocyte infusions following reduced intensity transplantation: toxicity, chimerism, and disease responses. Blood. 103:1548–1556.
Fozza, C., R.M. Szydlo, M.M. Abdel-Rehim, E. Nadal, J.M. Goldman, J.F. Apperley, and F. Dazzi. 2007. Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose. Br. J. Haematol. 136:833–836.[CrossRef][Medline]
Perreault, C., M. Pelletier, D. Landry, and M. Gyger. 1984. Study of Langerhans cells after allogeneic bone marrow transplantation. Blood. 63:807–811.
Collin, M.P., D.N. Hart, G.H. Jackson, G. Cook, J. Cavet, S. Mackinnon, P.G. Middleton, and A.M. Dickinson. 2006. The fate of human Langerhans cells in hematopoietic stem cell transplantation. J. Exp. Med. 203:27–33.
Auffermann-Gretzinger, S., L. Eger, M. Bornhauser, K. Schakel, U. Oelschlaegel, M. Schaich, T. Illmer, C. Thiede, and G. Ehninger. 2006. Fast appearance of donor dendritic cells in human skin: dynamics of skin and blood dendritic cells after allogeneic hematopoietic cell transplantation. Transplantation. 81:866–873.[CrossRef][Medline]
Lampert, I.A., G. Janossy, A.J. Suitters, M. Bofill, S. Palmer, E. Gordon-Smith, H.G. Prentice, and J.A. Thomas. 1982. Immunological analysis of the skin in graft versus host disease. Clin. Exp. Immunol. 50:123–131.[Medline]
Hymes, S.R., E.R. Farmer, P.G. Lewis, P.J. Tutschka, and G.W. Santos. 1985. Cutaneous graft-versus-host reaction: prognostic features seen by light microscopy. J. Am. Acad. Dermatol. 12:468–474.[Medline]
Lever, R., M. Turbitt, R. Mackie, I. Hann, B. Gibson, A. Burnett, and M. Willoughby. 1986. A prospective study of the histological changes in the skin in patients receiving bone marrow transplants. Br. J. Dermatol. 114:161–170.[CrossRef][Medline]
Yoo, Y.H., B.S. Park, D. Whitaker-Menezes, R. Korngold, and G.F. Murphy. 1998. Dermal dendrocytes participate in the cellular pathology of experimental acute graft-versus-host disease. J. Cutan. Pathol. 25:426–434.[CrossRef][Medline]
Deguchi, M., S. Aiba, H. Ohtani, H. Nagura, and H. Tagami. 2002. Comparison of the distribution and numbers of antigen-presenting cells among T-lymphocyte-mediated dermatoses: CD1a+, factor XIIIa+, and CD68+ cells in eczematous dermatitis, psoriasis, lichen planus and graft-versus-host disease. Arch. Dermatol. Res. 294:297–302.[Medline]
Bogunovic, M., F. Ginhoux, A. Wagers, M. Loubeau, L.M. Isola, L. Lubrano, V. Najfeld, R.G. Phelps, C. Grosskreutz, E. Scigliano, et al. 2006. Identification of a radio-resistant and cycling dermal dendritic cell population in mice and men. J. Exp. Med. 203:2627–2638.
Collin, M.P., M. Bogunovic, and M. Merad. 2007. DC homeostasis in hematopoietic stem cell transplantation. Cytotherapy. 9:521–531.[CrossRef][Medline]
Smythies, L.E., M. Sellers, R.H. Clements, M. Mosteller-Barnum, G. Meng, W.H. Benjamin, J.M. Orenstein, and P.D. Smith. 2005. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J. Clin. Invest. 115:66–75.[CrossRef][Medline]
Denning, T.L., Y.C. Wang, S.R. Patel, I.R. Williams, and B. Pulendran. 2007. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat. Immunol. 8:1086–1094.[CrossRef][Medline]
Belz, G.T., S. Bedoui, F. Kupresanin, F.R. Carbone, and W.R. Heath. 2007. Minimal activation of memory CD8+ T cell by tissue-derived dendritic cells favors the stimulation of naive CD8+ T cells. Nat. Immunol. 8:1060–1066.[CrossRef][Medline]
Cooper, K.D., G.R. Neises, and S.I. Katz. 1986. Antigen-presenting OKM5+ melanophages appear in human epidermis after ultraviolet radiation. J. Invest. Dermatol. 86:363–370.[CrossRef][Medline]
Bolognia, J.L., A. Lin, and P.E. Shapiro. 1994. The significance of eccentric foci of hyperpigmentation (small dark dots) within melanocytic nevi. Analysis of 59 cases. Arch. Dermatol. 130:1013–1017.
Unver, N., P. Freyschmidt-Paul, S. Horster, H. Wenck, F. Stab, T. Blatt, and H.P. Elsasser. 2006. Alterations in the epidermal-dermal melanin axis and factor XIIIa melanophages in senile lentigo and ageing skin. Br. J. Dermatol. 155:119–128.[CrossRef][Medline]
Handerson, T., A. Berger, M. Harigopol, D. Rimm, C. Nishigori, M. Ueda, E. Miyoshi, N. Taniguchi, and J. Pawelek. 2007. Melanophages reside in hypermelanotic, aberrantly glycosylated tumor areas and predict improved outcome in primary cutaneous malignant melanoma. J. Cutan. Pathol. 34:679–686.[CrossRef][Medline]
Cupurdija, K., D. Azzola, U. Hainz, A. Gratchev, A. Heitger, O. Takikawa, S. Goerdt, R. Wintersteiger, G. Dohr, and P. Sedlmayr. 2004. Macrophages of human first trimester decidua express markers associated to alternative activation. Am. J. Reprod. Immunol. 51:117–122.[CrossRef][Medline]
Torocsik, D., H. Bardos, L. Nagy, and R. Adany. 2005. Identification of factor XIII-A as a marker of alternative macrophage activation. Cell. Mol. Life Sci. 62:2132–2139.[CrossRef][Medline]
Caux, C., B. Vanbervliet, C. Massacrier, C. Dezutter-Dambuyant, B. de Saint-Vis, C. Jacquet, K. Yoneda, S. Imamura, D. Schmitt, and J. Banchereau. 1996. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF
. J. Exp. Med. 184:695–706.
Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, I. Durand, M. Cella, A. Lanzavecchia, and J. Banchereau. 1997. CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor alpha: II. Functional analysis. Blood. 90:1458–1470.
Hill, G.R., and J.L. Ferrara. 2000. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 95:2754–2759.
Jun, H.S., C.S. Yoon, L. Zbytnuik, N. van Rooijen, and J.W. Yoon. 1999. The role of macrophages in T cell–mediated autoimmune diabetes in nonobese diabetic mice. J. Exp. Med. 189:347–358.
Pozzi, L.A., J.W. Maciaszek, and K.L. Rock. 2005. Both dendritic cells and macrophages can stimulate naive CD8 T cells in vivo to proliferate, develop effector function, and differentiate into memory cells. J. Immunol. 175:2071–2081.
Mackay, C.R., W.L. Marston, and L. Dudler. 1990. Naive and memory T cells show distinct pathways of lymphocyte recirculation. J. Exp. Med. 171:801–817.
Clark, R.A., B. Chong, N. Mirchandani, N.K. Brinster, K. Yamanaka, R.K. Dowgiert, and T.S. Kupper. 2006. The vast majority of CLA+ T cells are resident in normal skin. J. Immunol. 176:4431–4439.
Sallusto, F., D. Lenig, R. Forster, M. Lipp, and A. Lanzavecchia. 1999. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 401:708–712.[CrossRef][Medline]
Chen, B.J., X. Cui, G.D. Sempowski, C. Liu, and N.J. Chao. 2004. Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease. Blood. 103:1534–1541.
Anderson, B.E., J. McNiff, J. Yan, H. Doyle, M. Mamula, M.J. Shlomchik, and W.D. Shlomchik. 2003. Memory CD4+ T cells do not induce graft-versus-host disease. J. Clin. Invest. 112:101–108.[CrossRef][Medline]
Crowe, S.R., S.J. Turner, S.C. Miller, A.D. Roberts, R.A. Rappolo, P.C. Doherty, K.H. Ely, and D.L. Woodland. 2003. Differential antigen presentation regulates the changing patterns of CD8+ T cell immunodominance in primary and secondary influenza virus infections. J. Exp. Med. 198:399–410.
This article has been cited by other articles:
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| TABLE OF CONTENTS |
|